Princess Maxima Center for Pediatric Oncology
Quick facts
Marketed products
- intrathecal chemotherapy · Oncology
Intrathecal chemotherapy delivers chemotherapeutic agents directly into the cerebrospinal fluid to treat central nervous system malignancies and prevent leptomeningeal disease.
Phase 1 pipeline
- anti-GD2-800CW
A fluorescent antibody conjugate that binds to GD2 on tumor cells, enabling optical imaging during surgery. - chemotherapy treatment called GPOH
- chemotherapy treatment called rapid COJEC
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Princess Maxima Center for Pediatric Oncology portfolio CI brief
- Princess Maxima Center for Pediatric Oncology pipeline updates RSS
Frequently asked questions about Princess Maxima Center for Pediatric Oncology
What are Princess Maxima Center for Pediatric Oncology's marketed drugs?
Top marketed products include intrathecal chemotherapy.
Related
- intrathecal chemotherapy · Oncology
- Sector hub: All tracked pharma companies